ArticleFrontiers in oncology2025
An exceptional oncological enigma: primary renal Ewing sarcoma in a clinical context-a case report.
Article in Frontiers in oncology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Primary renal Ewing sarcoma/primitive neuroectodermal tumor (PNET) is a very rare and aggressive malignant tumor. We report a case of a young adult who presented with painless hematuria and acute urinary retention and was subsequently diagnosed with localized left renal Ewing sarcoma following robotic-assisted retroperitoneal partial nephrectomy. Histopathology revealed a tumor composed of nests and lobules of monotonous tumor cells with round nuclei, indistinct nucleoli, and scanty cytoplasm, associated with a vascular-rich to hyalinized stroma and fibrillary neural matrix. Moderate nuclear pleomorphism, scattered necrosis, and pseudorosette formation were noted. Immunohistochemical studies demonstrated tumor cell positivity for CD99 and CD117. The patient was subjected to chemotherapy. Early diagnosis and multimodality treatment play an important role in improving survival rate.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.